[76Br]BMK‐152, a nonpeptide analogue, with high affinity and low nonspecific binding for the corticotropin‐releasing factor type 1 receptor
Abstract
Corticotropin‐releasing factor (CRF), a neuropeptide, regulates endocrine and autonomic responses to stress through G‐protein coupled receptors, CRF1or CRF2. A PET ligand able to monitor changes in CRF1receptor occupancy in vivo would aid in understanding the pathophysiology of stress‐related diseases as well as in the clinical development of nonpeptide antagonists with therapeutic value. We have radiolabeled the CRF1receptor ligand, [8‐(4‐bromo‐2,6‐dimethoxyphenyl)‐2,7‐dimethylpyrazolo[1,5‐α][1,3,5]triazin‐4‐yl]‐N,N‐bis‐(2‐methoxyethyl)amine (BMK‐152) (ClogP = 2.6), at both the 3 and 4 position with [76Br]. Using in vitro autoradiography saturation studies the 4‐[76Br]BMK‐152 exhibited high affinity binding to both rat (Kd= 0.23 ± 0.07 nM;n= 3) and monkey frontal cortex (Kd= 0.31 ± 0.08 nM;n= 3) consistent with CRF1receptor regional distribution whereas with the 3‐[76Br]BMK‐152, theKds could not be determined due to high nonspecific binding. In vitro autoradiography competition studies using [125I]Tyr0‐o‐CRF confirmed that 3‐Br‐BMK‐152 (Ki= 24.4 ± 4.9 nM;n= 3) had lower affinity (70‐fold) than 4‐Br‐BMK‐152 (Ki= 0.35 ± 0.07 nM;n= 3) in monkey frontal cortex and similiar studies using [125I]Sauvagine confirmed CRF1receptor selectivity. In vivo studies with P‐glycoprotein (PGP) knockout mice (KO) and their wild‐type littermates (WT) showed that the brain uptake of 3‐[76Br]BMK/4‐[76Br]BMK was increased less than twofold in KO versus WT indicating that 3‐[76Br]BMK‐152/4‐[76Br]BMK was not a Pgp substrate. Rat brain uptakes of 4‐[76Br] BMK‐152 from ex vivo autoradiography studies showed regional localization consistent with known published CRF1receptor distribution and potential as a PET ligand for in vivo imaging of CRF1receptors. Synapse 2011. Published 2011 Wiley‐Liss, Inc.Keywords
This publication has 53 references indexed in Scilit:
- Progress in corticotropin-releasing factor-1 antagonist developmentDrug Discovery Today, 2010
- Transient Early-Life Forebrain Corticotropin-Releasing Hormone Elevation Causes Long-Lasting Anxiogenic and Despair-Like Changes in MiceJournal of Neuroscience, 2010
- Neurobiological mechanisms contributing to alcohol–stress–anxiety interactionsAlcohol, 2009
- Role of CRF Receptor Signaling in Stress Vulnerability, Anxiety, and DepressionAnnals of the New York Academy of Sciences, 2009
- Achieving signalling selectivity of ligands for the corticotropin‐releasing factor type 1 receptor by modifying the agonist's signalling domainBritish Journal of Pharmacology, 2007
- PET Imaging of CRF1 with [11C]R121920 and [11C]DMP696: is the target of sufficient density?Nuclear Medicine and Biology, 2007
- Evidence that corticotropin‐releasing factor receptor type 1 couples to Gs‐ and Gi‐proteins through different conformations of its J‐domainBritish Journal of Pharmacology, 2006
- Experiment assessment of mass effects in the rat: implications for small animal PET imagingNuclear Medicine and Biology, 2004
- Ligand Affinity for Amino-Terminal and Juxtamembrane Domains of the Corticotropin Releasing Factor Type I Receptor: Regulation by G-Protein and Nonpeptide AntagonistsBiochemistry, 2004
- Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brainJournal of Comparative Neurology, 1999